UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
----------
Date of Report (Date of earliest event reported): April 18, 2007
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
Florida 000-27836 65-0643773
------------------------- ---------------- ----------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
2 Snunit Street
Science Park
POB 455
Carmiel, Israel 21000
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Registrant's telephone number, including area code: +972-4-988-9488
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On April 18, 2007, Protalix BioTherapeutics, Inc. (the "Company") issued a press
release announcing that had received written notice from the United States Food
and Drug Administration that it may initiate a Phase III clinical trial in the
United States of its lead product candidate, prGCD.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press release dated April 18, 2007
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROTALIX BIOTHERAPEUTICS, INC.
Date: April 18, 2007 By: /s/ David Aviezer
-----------------------
Name: David Aviezer, Ph.D.
Title: President and
Chief Executive Officer
2